Immunosuppressive Effect of Exosomes from Mesenchymal Stromal Cells in Defined Medium on Experimental Colitis

Zhi Jie Ma; Yun Hong Wang; Zhi Gang Li; Ying Wang; Bing Yao Li; Hui Yan Kang; Xiao Yun Wu

doi:10.15283/ijsc18139

Journal List > Int J Stem Cells > v.12(3) > 1159030

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ma, Wang, Li, Wang, Li, Kang, and Wu: Immunosuppressive Effect of Exosomes from Mesenchymal Stromal Cells in Defined Medium on Experimental Colitis

Original Article

International Journal of Stem Cells 2019; 12(3): 440-448.

Published online: 30 June 2019

DOI: https://doi.org/10.15283/ijsc18139

Immunosuppressive Effect of Exosomes from Mesenchymal Stromal Cells in Defined Medium on Experimental Colitis

Zhi Jie Ma¹, Yun Hong Wang², Zhi Gang Li³, Ying Wang⁴, Bing Yao Li⁵, Hui Yan Kang^2,³, Xiao Yun Wu^2,³

¹Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China

²Department of Technology, Stem Cell Medicine Engineering & Technology Research Center of Inner Mongolia, Huhhot, Inner Mongolia, China

³Department of Research and Development, Beijing Jingmeng Stem Cell Technology CO., LTD, Beijing, China

⁴Health Examination Center, Tongliao City Hospital, Tongliao, Inner Mongolia, China

⁵Department of Medicine, Chifeng Cancer Hospital, Chifeng, Inner Mongolia, China

Correspondence to: Xiao Yun Wu, Department of Research and Development, Beijing Jingmeng Stem Cell Technology CO., LTD, No. 5-2 Shangdi East Road, Haidian District, Beijing 100085, China, Tel: +86-010-51557697-8230, Fax: +86-010-51557697-8099, E-mail: stemcells@foxmail.com

Received 24 December 2018 Revised 4 April 2019 Accepted 11 April 2019

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Objectives

The exosomes released by mesenchymal stromal cells (MSCs) in classical FBS-containing media have been demonstrated as an alternative, cell-free therapy in various diseases including inflammatory bowel disease (IBD). It has been found that the function of exosomes is affected by culture condition. We previously developed a serum-free, xeno-free and chemically defined medium, and umbilical cord-derived MSCs in this medium retained the immunosuppressive capability.

Methods

In this study, we evaluated the immunosuppressive function of exosomes from MSCs (MSC-Exo) in defined medium and their therapeutic effect on treating colitis.

Results and Conclusions

In vitro studies indicated that MSC-Exo reduced the concentration of pro-inflammatory cytokines IFN-γ, TNF-α and IL-1β, and increased the secretion of anti-inflammatory cytokines TGF-β1 and IL-10, but no significant change of inhibitory effect on peripheral blood mononuclear cells proliferation was shown. In vivo experimental colitis showed that administration of MSC-Exo was able to significantly ameliorate the disease activity index score, weight loss, colon shortening, and the histological colitis score through up-regulation anti-inflammatory responses and down-regulation of inflammatory responses. Moreover, the use of MSC-Exo (200 μg) led to an improved therapeutic efficacy when compared with MSCs at a dose of 1×10⁶ cells. Our findings indicate that the exosomes from MSCs in defined medium possess a certain degree of immunosuppressive effect in vitro and exhibit a therapeutic capability in a mouse model of DSS-induced colitis through suppressing inflammation mechanism.

Keywords: Mesenchymal stromal cells, Colitis, Immunosuppressive effect, Serum free, Exosome

Introduction

Inflammatory bowel disease (IBD) represents a group of inflammatory disorder conditions of the gastrointestinal tract. There are a large number of patients suffering from IBD worldwide, which leads to a diminished quality of life and sometimes even death. Over the last decade, mesenchymal stromal cells (MSCs) have reported as an attractive therapy strategy in the treatment of IBD because of their immunosuppressive effect (1). Accumulating evidence suggests that the immunosuppressive effect of MSCs is, at least in part, mediated by exosomes (2, 3). Exosomes are extracellular membrane-enclosed microvesicles (40~100 nm) that many important components including proteins, microRNA, and mRNA (4). Recent studies have shown encouraging therapeutic activities of MSCs-derived exosomes (MSC-Exo) in various inflammatory-related animal models (5–7), although MSC-Exo are not as effective as their in anti-inflammatory ability in vitro (8–11). Compared with their cellular counterpart, exosomes may be safer and affordable, and could be easily stored without loss of function (12). Thus, MSC-Exo have led to the development of cell-free therapeutic approach as a safe and more advantageous alternative to MSCs-based therapy strategy (13–15). Recently, some studies have investigated that the therapeutic efficacy of secretome, extracts or conditioned medium from MSCs in animal model of induced colitis (16–19).

The result of preclinical research is encouraging, but the major barriers to clinical studies include standardized characterization and safety issue of MSC-Exo. Exosomes-based therapy needs clinically significant numbers of well-defined, safe, and efficient MSCs. Currently, the exosomes used in these studies are prepared from MSCs supplemented with classical fetal bovine serum (FBS). FBS is an animal-derived product, and its usage has raised safety concern because it might be a source of zoonotic infections and xenogenic antigens. It has been reported that commercial FBS (20~50%) is virus-positive (20). A study has reported that FBS proteins (7~30 mg) are linked to a standard preparation of 1×10⁸ MSCs (21). If so, it’s very possible that preparation of exosomes from MSCs grown in FBS carries a certain amount of FBS proteins, which can lead to immunological reactions when transplanted into the body (22–24). Moreover, FBS has unknown exact composition, and the batch-to-batch variability can ultimately lead to variations in cells and exosomes performance (20). For these reasons, the regulatory authorities encourage the usage of chemically-defined media as an alternative to FBS, especially for clinical-grade production of MSCs and MSC-Exo (25). Evaluation of the therapeutic potential and application of MSC-Exo in future clinical trials demands production under serum-free and xeno-free, and defined medium conditions (26, 27). The usage of defined medium will be very advantageous for reproducibility of exosomes production.

We previously developed for the first time, in the literature to date, a serum and xeno-free, chemically defined and no plate-coating-based culture system for the isolation and expansion of MSCs (28). Umbilical cord-derived MSCs cultured in this chemically defined medium fulfilled the biological characteristics of MSCs, and retained the similar immunosuppressive capability with those in classical FBS-containing media. Thus, we speculate that MSC-Exo in defined medium may also mimic the beneficial effects of MSCs in the immunosuppressive capability. In this study, we investigated the immunosuppressive function in vitro and the therapeutic potential of MSC-Exo in defined medium in a mice model of colitis.

Materials and Methods

Ethics statement

This study was approved by Ethics Committee of the Beijing Friendship Hospital affiliated to Capital Medical University. All animal experiments were conducted in accordance with the relevant guidelines and regulations of Animal Ethics Committee of the Beijing Friendship Hospital affiliated to Capital Medical University.

Production of umbilical cord-derived MSCs

The umbilical cord samples were obtained from healthy pregnant women. All women provided written informed consent. UCMSCs were prepared as described previously (28). The cord was rinsed with phosphate-buffered saline (PBS). The vessels were removed. Wharton’s jelly tissues were cut into 1~2 mm³ pieces and digested for 60 min in an enzyme cocktail (hyaluronidase 5 U/mL, collagenase 125 U/mL and dispase 50 U/mL; Sigma, St. Louis, MO, USA) at 37°C in a shaking incubator. The total nucleated cells were filtered through a 70 μM mesh and plated in xeno-free defined medium at 37°C, 5% CO₂. The defined medium was prepared as described previously (28). After removing non-adherent cells on 5 days, the adherent cells were passaged when reached 90% confluences. UCMSCs at passages 5 were used for experiments.

Preparation of MSC-Exo

UCMSCs were conditioned in PBS for 48 h at 90% confluence. Exosomes were prepared from the conditioned PBS according to the method previously described (29). Briefly, PBS was collected and centrifuged at 500 ×g for 10 min, 3000 ×g for 20 min and 10000 ×g for 30 min to remove cells and debris. The supernatant was ultra-centrifuged at 100000 ×g for 100 min to collect the exosomes. The MSC-Exo were resuspended in PBS and filtered with a 0.22-μm microcentrifuge filter. The protein concentration was determined by BCA kit.

Characterization of MSC-Exo

The morphology of MSC-Exo was examined using a transmission electron microscope, and the size distribution was determined by a Zetasizer Nano ZS (Malvern Instruments, UK) according to the manufacturer’s instructions. The exosome-associated proteins including CD9, CD63 and CD81 were analyzed using western blotting.

Co-culture of PBMCs with MSC-Exo

PBMCs were obtained via Ficoll separation from healthy donors, who provided written informed consent. PBMCs (5×10⁵ cells/well in 96-well culture plate) were plated in RPMI 1640 medium containing 10% FBS, 10 μg/ml phytohemagglutinin (PHA, Sigma-Aldrich) and 0, 5 or 20 μg MSC-Exo. After 72 h, cultures were pulsed with cell counting kit-8 reagent (Dojindo, Kumamoto, Japan) and measured with a Model 450 microplate reader. The inflammatory cytokines was analyzed in supernatant by ELISA (BD, Biosciences, San Jose, CA, USA).

Colitis induction and treatment procedure

C57BL/6 mice (6~8 weeks) were administered with 2.5% DSS in the drinking water from day 1 to day 7. The mice were administered with MSC-Exo (200 μg/mouse) or MSCs (1×10⁶ cells/mouse) in 200 μL PBS by intraperitoneal injection on day 2, and sacrificed on day 10. 200 μL PBS was injected into DSS-treated mice as control group, while the mice that received drinking DSS-free water were used as normal group.

Clinical symptoms evaluation

Body weight was monitored daily, stool consistency and bleeding severity were recorded on day 10, and DAI was assessed (Supplementary Table S1).

Colon length examination

Colon was surgically separated and the length was measured on day 10.

Histological evaluation

Colon tissue samples were fixed in 4% paraformaldehyde, prepared and stained with hematoxylin and eosin (H&E staining). The intensity of inflammation was evaluated by histological score (Supplementary Table S2).

Cytokines assays

The colon was homogenized in lysis buffer containing 1% Triton X-100 and protease inhibitor cocktail and centrifuged at 13000 ×g for 20 min to collect the supernatant. The total protein concentration was determined by BCA Protein Assay. The levels of inflammatory cytokines such as IFN-γ, TNF-α, IL-6, IL-17, IL-10, and TGF-β1 were quantitatively measured by ELISA and corrected for the amount of total protein.

Statistical analysis

Data are expressed as the means±standard deviation (SD) of at least three experiments. The differences among groups were analyzed by one-way ANOVA. p<0.05 was considered statistically significant.

Results

Characterization of MSC-Exo

To validate whether exosomes were successfully isolated from UCMSCs cultured in defined medium, the characterization tests were performed. Transmission electron microscopy analysis showed spheroid shape of MSC-Exo, with a diameter between 40 and 100 nm (Fig. 1A). The particle size distribution of MSC-Exo was recorded (Fig. 1B). The MSC-Exo expressed CD9, CD63, and CD81 (Fig. 1C). These results demonstrate that we have successfully isolated and identified exosomes from UCMSCs cultured in defined medium.

Fig. 1

Characteristics of MSC-Exo. (A) Transmission electron microscopy analysis of exosomes secreted by UCMSCs cultured in defined medium. Scale bar: 50 nm. (B) CD63, CD9, and CD81 expressions in MSC-Exo were detected by western blotting. (C) The size distribution profile of MSC-Exo.

MSC-Exo possessed a certain degree of immunosuppressive capability in vitro

Different levels of MSC-Exo were used to treat PBMCs. When in high concentration (20 μg) of MSC-Exo, the concentration of IFN-γ (Fig. 2A), TNF-α (Fig. 2B) and IL-1β (Fig. 2C) was significantly decreased, while TGF-β1 (Fig. 2D) and IL-10 (Fig. 2E) significantly increased compared with no MSC-Exo group. In consistence with the results in high concentration, the significant decrease of IFN-γ (Fig. 2A) and TNF-α (Fig. 2B) and increase of TGF-β1 (Fig. 2D) were also showed in low concentration (5 μg) of MSC-Exo. However, no significant differences in the level of IL-1β and IL-10 were detected (Fig. 2C and 2E). Moreover, MSC-Exo at these two concentrations had no effect on inhibiting the proliferation of peripheral blood mononuclear cells (PBMCs) (Fig. 2F). These data suggest that MSC-Exo possess a certain degree of immunosuppressive capability in vitro.

Fig. 2

MSC-Exo possessed a certain degree of immunosuppressive capability in vitro. The concentrations of the pro-inflammatory cytokines (A) IFN-γ, (B) TNF-α and (C) IL-1β and anti-inflammatory cytokines (D) TGF-β1 and (E) IL-10 were measured in the supernatant of PBMCs treated with different levels of MSC-Exo for 72 h. (F) The proliferation of PBMCs was evaluated after culture with different levels of MSC-Exo. Bars indicate means±SD. n=5; *p<0.05, **p<0.01, and ***p<0.001.

MSC-Exo or MSCs alleviated clinical symptom in DSS-induced colitis mice

To assess whether administering MSC-Exo ameliorated colitis, we used 2.5% DSS for 7 days to establish experimental models of DSS-induced colitis, and administered 200 μg MSC-Exo on days 2. The MSCs (1×10⁶) cultivated in defined medium were used as counterpart, and the same procedures performed. All the mice were sacrificed on day 10 (Fig. 3A). Our result showed that the administration of MSCs or MSC-Exo significantly improved clinical parameters including body weight (Fig. 3B) and disease activity index (DAI, Fig. 3C) compared with PBS-treated mice, suggesting that MSC-Exo significantly alleviated clinical symptom in DSS-induced colitis. In addition, 200 μg MSC-Exo significantly ameliorated the parameters compared with 1×10⁶ MSCs-treated mice (Fig. 3B and 3C).

Fig. 3

MSC-Exo or MSCs alleviated clinical symptom in DSS-induced colitis mice. (A) Scheme of study design. (B) Body weight was monitored daily. (C) Disease activity index (DAI) scores were measured on day 10. Bars indicate means±SD. n=5~8; *p<0.05 and **p<0.01.

MSC-Exo or MSCs alleviated colonic damage in DSS-induced colitis mice

To further investigate whether administering MSC-Exo alleviated colonic damage, the quantitative evaluation of colon length and histopathological examination was performed. Our result showed that the administration of MSCs or MSC-Exo significantly alleviated colonic damages such as colon length (Fig. 4A and 4B) and histological severity (Fig. 4C and 4D), suggesting that MSC-Exo or MSCs significantly alleviated colonic damage in DSS-induced colitis. In addition, the histopathological scoring in the MSC-Exo group was significantly lower than the MSCs group (Fig. 4D), although no significant difference in colon length was shown between two groups (Fig. 4B).

Fig. 4

MSC-Exo or MSCs alleviated colonic damage in DSS-induced colitis mice. (A) Representative images of colon length. (B) Colon length was quantitatively analyzed. (C) Representative H&E staining, bar=100 μm. (D) Corresponding severity score was determined. Bars indicate means± SD. n=5~8; *p<0.05.

MSC-Exo or MSCs reduced the inflammatory state in DSS-induced colitis mice

To characterize this therapeutic mechanism, we measured the inflammatory cytokines in colon tissue. The pro-inflammatory cytokines including IFN-γ (Fig. 5A), TNF-α (Fig. 5B), IL-6 (Fig. 5C), and IL-17 (Fig. 5D) were significantly down-regulated, while anti-inflammatory cytokines including IL-10 (Fig. 5E) and TGF-β1 (Fig. 5F) were significantly up-regulated in the MSCs or MSC-Exo-treated mice compared with the PBS-treated mice. These data suggest that MSC-Exo or MSCs significantly reduced the inflammatory state in DSS-induced colitis mice. Moreover, the levels of TNF-α (Fig. 5B), IL-6 (Fig. 5C), and IL-17 (Fig. 5D) were decreased, while IL-10 (Fig. 5E) and TGF-β1 (Fig. 5F) increased in the colon after treatment with MSC-Exo at a dose of 200 μg compared with 1×10⁶ MSCs. In addition, IFN-γ was not significant change after MSC-Exo treatment compared with MSCs (Fig. 5A).

Fig. 5

MSC-Exo or MSCs reduced the infammatory state in DSS-induced colitis mice. The concentrations of the pro-inflammatory cytokines (A) IFN-γ, (B) TNF-α, (C) IL-6 and (D) IL-17 and anti-inflammatory cytokines (E) IL-10 and (F) TGF-β1 in colonic protein extracts were measured by ELISA. Bars indicate mean±SD, n=5~8; *p<0.05, **p<0.01 and ***p<0.001.

Discussion

The current study demonstrates that the exosomes from MSCs in defined medium possess a certain degree of immunosuppressive effect in vitro and exhibit a therapeutic capability in a mouse model of DSS-induced colitis through suppressing inflammation mechanism. To the best of our knowledge, this is the first report of defined medium-derived MSC-Exo. The translation of therapeutically valuable MSC-Exo into a therapeutic agent presents several major considerations including standardized characterization and safety issue of MSC-Exo. The usage of defined medium will be very advantageous for these considerations. Exosomes, one of several groups of extracellular vesicles released by MSCs, may exert different functions via the release of different kinds of molecules, depending on the cell culture environment (30). Further study is needed to answer whether the immunosuppressive effect of exosomes from MSCs cultured in defined medium is different from those in classical FBS-supplemented medium.

The increasing evidence has shown that the inhibitory effect of MSC-Exo on lymphocyte proliferation is minor when compared to their parental cells (8–10). Here, MSC-Exo failed to suppress PBMCs proliferation at dose levels up to 20 μg/mL, while MSCs in defined medium exhibit this response (28). This result is consistent with previous reports on MSC-Exo from various sources in FBS or platelet lysate-based medium (9–11), suggesting that this phenomenon is independent of culture conditions and sources. Further research is needed to answer whether MSC-Exo have an immunosuppressive role on the different immune cell subsets. Furthermore, our result showed that MSC-Exo reduced the concentration of pro-inflammatory cytokines and increased the secretion of anti-inflammatory cytokines during in vitro culture, suggesting that MSC-Exo display a certain degree of immunosuppressive activity. Similar fashion has been reported in FBS-based study (8, 11). The immunosuppressive potential of MSC-Exo has been actively observed and in vivo, although not as effective as their cellular counterpart (2, 6–8, 31, 32).

The second key finding in this study is that the single intraperitoneal injection of MSC-Exo in defined medium was able to significantly alleviate the clinical symptom and colonic damage in DSS-induced colitis. This result is consistent with previous studies based on FBS (16, 18, 19, 33). Intraperitoneal injection is selected as the most common administration route for MSC-Exo delivery in DSS-induced colitis, based on previous studies (16, 34). In line with the clinical and histological evaluation, the MSC-Exo treatment significantly downregulated the expression level of pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-6, and IL-17, while upregulated anti-inflammatory cytokines such as IL-10 and TGF-β1. The performance of some cytokines is consistent in the previous study based on FBS (16, 18, 35), but some are different (19). The reason of differences remains unclear, but it may hint to the fact that culture condition may reflect the content of MSC-Exo and may therefore affect their potency. On the other hand, it cannot be excluded the differences of tissue source and method of isolation. In fact, multiple studies have confirmed the difference of exosomes caused by different sources and methods (13). Taken together, we suggest that MSC-Exo in defined medium exert therapeutic effects in a murine model of colitis through suppressing inflammation mechanism. Further functional in vivo and in vitro studies are needed to unveil the exact mechanism.

In addition, our results show that the use of MSC-Exo (200 μg) leads to an improved clinical symptom and histological severity in vivo when compared with MSCs at a dose of 1×10⁶ cells. One possible explanation is that exosomes act faster than cells. However, we did not detect differences in the colon length between MSCs and MSC-Exo treated mice. The reason is not known but we hypothesize that the in vivo environment is much more complex, or that the endpoints of evaluation was not appropriate. This is related to up-regulation anti-inflammatory responses and down-regulation of inflammatory responses. An increasing number of FBS-based studies have reported that MSC-Exo are equal or superior effectiveness as MSCs in various disease models (36–39), most studies are absence of comparable dosing, so it is difficult to draw conclusions about comparable therapeutic efficacy. The summary of the literature has shown some dose variations and a dose ranging (0.1~250 μg/animal) in various animal models (13). Some previous reports showed therapeutic effect of MSC-Exo at a dose of 200 μg or MSCs at a dose of 1×10⁶ cells in mice models of various diseases (33, 35, 40), and so defined as our dose in this study.

In conclusion, our results suggest the feasibility of MSC-Exo in defined medium for cell-free applications in the treatment of IBD. Additional studies are required to compare the composition and therapeutic benefits of exosomes from MSCs in defined medium and FBS-containing media.

Supplementary Information

IJSC-12-440_Supple.pdf

Acknowledgments

This work was supported by National Natural Science Foundation of China (No. 81860157) and Natural Science Foundation of Inner Mongolia (No. 2017MS0314).

Notes

Potential Conflict of Interest

The authors have no conflicting financial interest.

Supplementary Materials

Supplementary data including two tables can be found with this article online at http://pdf.medrang.co.kr/paper/pdf/IJSC/IJSC-12-s18139.pdf.

References

1. Algeri M, Conforti A, Pitisci A, Starc N, Tomao L, Bernardo ME, Locatelli F. Mesenchymal stromal cells and chronic inflammatory bowel disease. Immunol Lett. 2015; 168:191–200. DOI: 10.1016/j.imlet.2015.06.018. PMID: 26170204.

2. Silva AM, Teixeira JH, Almeida MI, Gonçalves RM, Barbosa MA, Santos SG. Extracellular vesicles: immunomodulatory messengers in the context of tissue repair/regeneration. Eur J Pharm Sci. 2017; 98:86–95. DOI: 10.1016/j.ejps.2016.09.017. PMID: 27644894.

3. Chang YH, Wu KC, Harn HJ, Lin SZ, Ding DC. Exosomes and stem cells in degenerative disease diagnosis and therapy. Cell Transplant. 2018; 27:349–363. DOI: 10.1177/0963689717723636. PMID: 29692195. PMCID: PMC6038041.

4. Taverna S, Pucci M, Alessandro R. Extracellular vesicles: small bricks for tissue repair/regeneration. Ann Transl Med. 2017; 5:83. DOI: 10.21037/atm.2017.01.53. PMID: 28275628. PMCID: PMC5337202.

5. Nojehdehi S, Soudi S, Hesampour A, Rasouli S, Soleimani M, Hashemi SM. Immunomodulatory effects of mesenchymal stem cell-derived exosomes on experimental type-1 autoimmune diabetes. J Cell Biochem. 2018; 119:9433–9443. DOI: 10.1002/jcb.27260. PMID: 30074271.

6. Casado JG, Blázquez R, Vela FJ, Álvarez V, Tarazona R, Sánchez-Margallo FM. Mesenchymal stem cell-derived exosomes: immunomodulatory evaluation in an antigen-induced synovitis porcine model. Front Vet Sci. 2017; 4:39. DOI: 10.3389/fvets.2017.00039. PMID: 28377922. PMCID: PMC5359696.

7. Tamura R, Uemoto S, Tabata Y. Immunosuppressive effect of mesenchymal stem cell-derived exosomes on a concanavalin A-induced liver injury model. Inflamm Regen. 2016; 36:26. DOI: 10.1186/s41232-016-0030-5. PMID: 29259699. PMCID: PMC5725906.

8. Conforti A, Scarsella M, Starc N, Giorda E, Biagini S, Proia A, Carsetti R, Locatelli F, Bernardo ME. Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev. 2014; 23:2591–2599. DOI: 10.1089/scd.2014.0091. PMID: 24937591. PMCID: PMC4201301.

9. Gouveia de Andrade AV, Bertolino G, Riewaldt J, Bieback K, Karbanová J, Odendahl M, Bornhäuser M, Schmitz M, Corbeil D, Tonn T. Extracellular vesicles secreted by bone marrow- and adipose tissue-derived mesenchymal stromal cells fail to suppress lymphocyte proliferation. Stem Cells Dev. 2015; 24:1374–1376. DOI: 10.1089/scd.2014.0563. PMID: 25779336.

10. Pachler K, Ketterl N, Desgeorges A, Dunai ZA, Laner-Plamberger S, Streif D, Strunk D, Rohde E, Gimona M. An in vitro potency assay for monitoring the immunomodulatory potential of stromal cell-derived extracellular vesicles. Int J Mol Sci. 2017; 18:pii: E1413. DOI: 10.3390/ijms18071413. PMID: 28671586. PMCID: PMC5535905.

11. Chen W, Huang Y, Han J, Yu L, Li Y, Lu Z, Li H, Liu Z, Shi C, Duan F, Xiao Y. Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunol Res. 2016; 64:831–840. DOI: 10.1007/s12026-016-8798-6. PMID: 27115513.

12. Cheng L, Zhang K, Wu S, Cui M, Xu T. Focus on mesenchymal stem cell-derived exosomes: opportunities and challenges in cell-free therapy. Stem Cells Int. 2017; 2017:6305295. DOI: 10.1155/2017/6305295. PMID: 29410682. PMCID: PMC5749272.

13. Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017; 35:851–858. DOI: 10.1002/stem.2575. PMID: 28294454.

14. Motavaf M, Pakravan K, Babashah S, Malekvandfard F, Masoumi M, Sadeghizadeh M. Therapeutic application of mesenchymal stem cell-derived exosomes: a promising cell-free therapeutic strategy in regenerative medicine. Cell Mol Biol (Noisy-le-grand). 2016; 62:74–79. PMID: 27453276.

15. Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R. The current landscape of the mesenchymal stromal cell secretome: a new paradigm for cell-free regeneration. Cytotherapy. 2016; 18:13–24. DOI: 10.1016/j.jcyt.2015.10.008. PMID: 26631828. PMCID: PMC4924535.

16. Pouya S, Heidari M, Baghaei K, Asadzadeh Aghdaei H, Moradi A, Namaki S, Zali MR, Hashemi SM. Study the effects of mesenchymal stem cell conditioned medium injection in mouse model of acute colitis. Int Immunopharmacol. 2018; 54:86–94. DOI: 10.1016/j.intimp.2017.11.001. PMID: 29112894.

17. Heidari M, Pouya S, Baghaei K, Aghdaei HA, Namaki S, Zali MR, Hashemi SM. The immunomodulatory effects of adipose-derived mesenchymal stem cells and mesenchymal stem cells-conditioned medium in chronic colitis. J Cell Physiol. 2018; 233:8754–8766. DOI: 10.1002/jcp.26765. PMID: 29797577.

18. Song JY, Kang HJ, Hong JS, Kim CJ, Shim JY, Lee CW, Choi J. Umbilical cord-derived mesenchymal stem cell extracts reduce colitis in mice by re-polarizing intestinal macrophages. Sci Rep. 2017; 7:9412. DOI: 10.1038/s41598-017-09827-5. PMID: 28842625. PMCID: PMC5573412.

19. Miyamoto S, Ohnishi S, Onishi R, Tsuchiya I, Hosono H, Katsurada T, Yamahara K, Takeda H, Sakamoto N. Therapeutic effects of human amnion-derived mesenchymal stem cell transplantation and conditioned medium enema in rats with trinitrobenzene sulfonic acid-induced colitis. Am J Transl Res. 2017; 9:940–952. PMID: 28386323. PMCID: PMC5375988.

20. van der Valk J, Bieback K, Buta C, Cochrane B, Dirks WG, Fu J, Hickman JJ, Hohensee C, Kolar R, Liebsch M, Pistollato F, Schulz M, Thieme D, Weber T, Wiest J, Winkler S, Gstraunthaler G. Fetal Bovine Serum (FBS): past - present - future. ALTEX. 2018; 35:99–118. DOI: 10.14573/altex.1705101. PMID: 28800376.

21. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther. 2004; 9:747–756. DOI: 10.1016/j.ymthe.2004.02.012. PMID: 15120336.

22. Sundin M, Ringdén O, Sundberg B, Nava S, Götherström C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica. 2007; 92:1208–1215. DOI: 10.3324/haematol.11446. PMID: 17666368.

23. Tonti GA, Mannello F. From bone marrow to therapeutic applications: different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera? Int J Dev Biol. 2008; 52:1023–1032. DOI: 10.1387/ijdb.082725gt. PMID: 18956335.

24. Owens SD, Kol A, Walker NJ, Borjesson DL. Allogeneic mesenchymal stem cell treatment induces specific alloantibodies in horses. Stem Cells Int. 2016; 2016:5830103. DOI: 10.1155/2016/5830103. PMID: 27648075. PMCID: PMC5018342.

25. Solomon J, Csontos L, Clarke D, Bonyhadi M, Zylberberg C, McNiece I, Kurtzberg J, Bell R, Deans R. Current perspectives on the use of ancillary materials for the manufacture of cellular therapies. Cytotherapy. 2016; 18:1–12. DOI: 10.1016/j.jcyt.2015.09.010. PMID: 26596503.

26. Pachler K, Lener T, Streif D, Dunai ZA, Desgeorges A, Feichtner M, Öller M, Schallmoser K, Rohde E, Gimona M. A good manufacturing practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles. Cytotherapy. 2017; 19:458–472. DOI: 10.1016/j.jcyt.2017.01.001. PMID: 28188071.

27. van der Valk J, Brunner D, De Smet K, Fex Svenningsen A, Honegger P, Knudsen LE, Lindl T, Noraberg J, Price A, Scarino ML, Gstraunthaler G. Optimization of chemically defined cell culture media--replacing fetal bovine serum in mammalian in vitro methods. Toxicol In Vitro. 2010; 24:1053–1063. DOI: 10.1016/j.tiv.2010.03.016. PMID: 20362047.

28. Wu X, Kang H, Liu X, Gao J, Zhao K, Ma Z. Serum and xeno-free, chemically defined, no-plate-coating-based culture system for mesenchymal stromal cells from the umbilical cord. Cell Prolif. 2016; 49:579–588. DOI: 10.1111/cpr.12279. PMID: 27492579.

29. Jo W, Kim J, Yoon J, Jeong D, Cho S, Jeong H, Yoon YJ, Kim SC, Gho YS, Park J. Large-scale generation of cell-derived nanovesicles. Nanoscale. 2014; 6:12056–12064. DOI: 10.1039/C4NR02391A. PMID: 25189198.

30. Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med. 2014; 12:260. DOI: 10.1186/s12967-014-0260-8. PMID: 25304688. PMCID: PMC4197270.

31. Börger V, Bremer M, Ferrer-Tur R, Gockeln L, Stambouli O, Becic A, Giebel B. Mesenchymal stem/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents. Int J Mol Sci. 2017; 18:pii: E1450. DOI: 10.3390/ijms18071450. PMID: 28684664. PMCID: PMC5535941.

32. Cosenza S, Toupet K, Maumus M, Luz-Crawford P, Blanc-Brude O, Jorgensen C, Noël D. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics. 2018; 8:1399–1410. DOI: 10.7150/thno.21072. PMID: 29507629. PMCID: PMC5835945.

33. Yang J, Liu XX, Fan H, Tang Q, Shou ZX, Zuo DM, Zou Z, Xu M, Chen QY, Peng Y, Deng SJ, Liu YJ. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis. PLoS One. 2015; 10:e0140551. DOI: 10.1371/journal.pone.0140551. PMID: 26469068. PMCID: PMC4607447.

34. Nikolic A, Simovic Markovic B, Gazdic M, Randall Harrell C, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, L Lukic M, Stojkovic M, Volarevic V. Intraperitoneal administration of mesenchymal stem cells ameliorates acute dextran sulfate sodium-induced colitis by suppressing dendritic cells. Biomed Pharmacother. 2018; 100:426–432. DOI: 10.1016/j.biopha.2018.02.060. PMID: 29471245.

35. Legaki E, Roubelakis MG, Theodoropoulos GE, Lazaris A, Kollia A, Karamanolis G, Marinos E, Gazouli M. Therapeutic potential of secreted molecules derived from human amniotic fluid mesenchymal stem/stroma cells in a mice model of colitis. Stem Cell Rev. 2016; 12:604–612. DOI: 10.1007/s12015-016-9677-1. PMID: 27503204.

36. Lou G, Chen Z, Zheng M, Liu Y. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med. 2017; 49:e346. DOI: 10.1038/emm.2017.63. PMID: 28620221. PMCID: PMC5519012.

37. Safari S, Malekvandfard F, Babashah S, Alizadehasl A, Sadeghizadeh M, Motavaf M. Mesenchymal stem cell-derived exosomes: a novel potential therapeutic avenue for cardiac regeneration. Cell Mol Biol (Noisy-le-grand). 2016; 62:66–73. PMID: 27453275.

38. Kishore R, Khan M. More than tiny sacks: stem cell exosomes as cell-free modality for cardiac repair. Circ Res. 2016; 118:330–343. DOI: 10.1161/CIRCRESAHA.115.307654. PMID: 26838317. PMCID: PMC4743531.

39. Tsao CR, Liao MF, Wang MH, Cheng CM, Chen CH. Mesenchymal stem cell derived exosomes: a new hope for the treatment of cardiovascular disease? Acta Cardiol Sin. 2014; 30:395–400. PMID: 27122816. PMCID: PMC4834956.

40. Park HJ, Kim J, Saima FT, Rhee KJ, Hwang S, Kim MY, Baik SK, Eom YW, Kim HS. Adipose-derived stem cells ameliorate colitis by suppression of inflammasome formation and regulation of M1-macrophage population through prostaglandin E2. Biochem Biophys Res Commun. 2018; 498:988–995. DOI: 10.1016/j.bbrc.2018.03.096. PMID: 29550474.

TOOLS

Similar articles